TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00447226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral lapatinib tablets or placebo tablets
Description: Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral lapatinib tablets or placebo tablets
Description: Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
Study: NCT03984110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: Intravitreal injection
Study: NCT03373578

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: earmuffs
Description: to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
Study: NCT02741622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High aerobic intensity training (HIT)
Description: One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long slow distance training (LSD)
Description: One training session, long slow distance training (LSD) at 70 % of the HRmax
Study: NCT01232868

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: trivalent Influenza vaccine (TIV)
Description: 0.5 ml IM as a single dose in a prefilled syringe.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: trivalent Influenza vaccine (TIV)
Description: 0.5 ml IM as a single dose in a prefilled syringe.
Study: NCT01013129

Intervention type: GENETIC
Intervention: DNA analysis
Description: saliva samples will be collected from men (probands) who join the study.

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: 10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses

Intervention type: OTHER
Intervention: medical chart review
Description: PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis

Intervention type: OTHER
Intervention: questionnaire administration
Description: probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study

Intervention type: PROCEDURE
Intervention: evaluation of cancer risk factors
Description: pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors

Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: prostate biopsy pathology reports will be reviewed for high risk factors
Study: NCT04393415

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: giving stem cells to patients with covid - 19

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: giving stem cells to patients with covid - 19
Study: NCT02831764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Description: Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Description: Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
Study: NCT03449758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SARILUMAB
Description: Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT02232022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ Insertable Cardiac Monitor
Study: NCT03798717

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heating
Description: Warm water immersion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heating
Description: Warm water immersion
Study: NCT00942903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provox Xtra HME
Description: Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
Study: NCT00884364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue counseling
Description: The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
Study: NCT04380506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Drains Management
Description: The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
Study: NCT03314493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25Mg Tablet
Description: Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
Study: NCT01804478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mild pneumatic compression
Study: NCT01609348

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule matching active drug to be taken once a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: 225 mg daily for 12 weeks
Study: NCT00101231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study: NCT04381858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma from COVID-19 convalescent patient
Description: Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human immunoglobulin
Description: Human immunoglobulin 0.3 gr/kg/day (5 doses)
Study: NCT03714178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE Endocardial Ablation System
Description: Endocardial ablation using the FARAPULSE Endocardial Ablation System.
Study: NCT01803425

Intervention type: OTHER
Intervention: Synflorix™ data collection
Description: Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
Study: NCT01808196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
Study: NCT03588663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline Bionic Leg Assessment
Description: The 'Bionic Leg' (BL) \[Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014\], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Control Condition Assessment
Description: Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Assessment
Description: 45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
Study: NCT00985673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (TIV)
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Single intramuscular injection
Study: NCT04760756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragility Fracture Integrated Rehabilitation Management
Description: * At least 2 hours of rehabilitation management per day~* Including occupational therapy (training to improve daily life performance)~* Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~* Outpatient (2-6 weeks): management once a week~* The management period is for 2 weeks (1 week after surgery)
Study: NCT00974142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifteen patients will receive will receive placebo.
Study: NCT03715517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous thoracic epidural analgesia
Description: Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with intrathecal morphine
Description: Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in \<5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% in Dextrose Inj 8.25%
Description: 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Preservative-Free Injectable Solution
Description: 0.25 mg⋅kg-¹ bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupicavaine 0.125% epidural solution
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 10 mcg/mL epidural solution
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
Study: NCT00291135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg daily
Study: NCT03057496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collision warning device
Description: The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
Study: NCT01100866

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: POMELLA™ (pomegranate extract)
Description: in a capsule form, 2 x 500mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study: NCT00989001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant
Description: Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection
Study: NCT04735835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
Study: NCT00786383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B
Description: Cohort 1~6 mg/kg I.V., once every other week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 2~8mg/kg I.V., once every other week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 3~10 mg/kg I.V., once every other week for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks
Study: NCT02136979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: group of patients with propofol-based anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: group of patients with sevoflurane-based anesthesia
Study: NCT02160756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-56021927 Softgel Capsule
Description: Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 Tablet Formulation 1
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 Tablet Formulation 2
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 Tablet Formulation 3
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.